Table 4 Comparison of the effect of inhalation exposure to CWAAP-A in this study and our previous 13-week study (reference: Takeda et al. [8])
Exposure protocol | Chamber condition | Â | Cumulative dose | LDH in BALF | Â |
|---|---|---|---|---|---|
Hours/day, days/week, total hour | MMAD (GSD) (μm) | Exposure concentration (mg/m3) | Dose (mg/m3 × h) | Average ± SD (U/L) | Fold change |
CWAAP-A (the present study, high-concentration intermittent exposure) | Â | Â | Â | Â | Â |
 Male F344/DuCrlCrlj rat |  |  |  |  |  |
  4 h/day, 1 day/week for 2 months (total 36 h) |  | 0 | – | 25 ± 1.1 | – |
0.8 (2.4) | 15 | 540 | 330 ± 11.7 | 13.0 | |
0.7 (2.4) | 40 | 1440 | 636 ± 129.8 | 25.0 | |
CWAAP-A (Our previous report: Reference: Takeda et al. [8]) | Â | Â | Â | Â | Â |
 Male F344/DuCrlCrlj rat |  | 0 | – | 25 ± 1.2 | – |
0.8 (2.7) | 0.3 | 117 | 62 ± 6.3 | 2.5 | |
0.8 (2.6) | 1 | 390 | 177 ± 13.6 | 7.1 | |
0.8 (2.6) | 3 | 1170 | 319 ± 17.6 | 12.8 | |
0.8 (2.7) | 10 | 3900 | 684 ± 46.9 | 27.4 | |
 Female F344/DuCrlCrlj rat |  | 0 | – | 29 ± 1.0 | – |
  6 h/day, 5 days/week for 13 weeks (total 390 h) | 0.8 (2.7) | 0.3 | 117 | 60 ± 4.1 | 2.0 |
0.8 (2.6) | 1 | 390 | 140 ± 16.6 | 4.8 | |
0.8 (2.6) | 3 | 1170 | 268 ± 10.4 | 9.2 | |
0.8 (2.7) | 10 | 3900 | 681 ± 83.0 | 23.3 |